Phase I study of oral azacitidine in myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemia

Journal of Clinical Oncology

Volumn 29, Issue 18, 2011, Pages 2521-2527

  Garcia Manero, Guillermo ^a   Gore, Steven D ^b   Cogle, Christopher ^c   Ward, Renee ^d   Shi, Tao ^d   MacBeth, Kyle J ^d   Laille, Eric ^d   Giordano, Heidi ^d   Sakoian, Sarah ^b   Jabbour, Elias ^a   Kantarjian, Hagop ^a   Skikne, Barry ^d,e  

^a UNIVERSITY OF TEXAS   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

^c UNIVERSITY OF FLORIDA   (United States)

^d CELGENE CORPORATION   (United States)

^e UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZACITIDINE; DNA;

ABDOMINAL PAIN; ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; CANCER REGRESSION; CHRONIC MYELOMONOCYTIC LEUKEMIA; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTUSION; COUGHING; DIARRHEA; DIZZINESS; DNA METHYLATION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE ESCALATION; DRUG FEVER; DRUG SAFETY; DRUG TOLERABILITY; ERYTHROCYTE TRANSFUSION; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HEADACHE; HUMAN; MALE; MAXIMUM TOLERATED DOSE; MYELODYSPLASTIC SYNDROME; NAUSEA; OPEN STUDY; PERIPHERAL EDEMA; PHARMACODYNAMICS; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; THROMBOCYTE TRANSFUSION; TREATMENT RESPONSE; VOMITING;

ADMINISTRATION, ORAL; ADULT; AGED; AGED, 80 AND OVER; ANTIMETABOLITES; ANTIMETABOLITES, ANTINEOPLASTIC; AZACITIDINE; BIOLOGICAL AVAILABILITY; DNA METHYLATION; FATIGUE; FEMALE; GASTROINTESTINAL DISEASES; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; LEUKEMIA, MYELOMONOCYTIC, CHRONIC; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; NEUTROPENIA;

EID: 79959318635     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2010.34.4226     Document Type: Article

References (14)

1. Hollenbach PW, Nguyen AN, Brady H, et al: A comparison of azacitidine and decitabine activities in acute myeloid leukemia cell lines. PLoS One 5:e9001, 2010
2. D'Alò F, Voso MT, Leone G: Profile of azacitidine. Therapy 2:717-731, 2005 (Pubitemid 41447760)
3. Gore SD, Baylin S, Sugar E, et al: Combined DNA methyltransferase and histone deacetylase inhibition in the treatment of myeloid neoplasms. Cancer Res 66:6361-6369, 2006
4. Streseman C, Bokelmann I, Mahlknecht U, et al: Azacytidine causes complex DNA methylation responses in myeloid leukemia. Mol Cancer Ther 7:2998-3005, 2008
5. Garcia-Manero G, Stoltz ML, Ward MR, et al: A pilot pharmacokinetic study of oral azacitidine. Leukemia 22:1680-1684, 2008
6. Vardiman JW, Harris NL, Brunning RD: The World Health Organization (WHO) classification of the myeloid neoplasms. Blood 100:2292-2302, 2002
7. Vardiman JW, Thiele J, Arber DA, et al: The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: Rationale and important changes. Blood 114:937-951, 2009
8. Troyanskaya O, Cantor M, Sherlock G, et al: Missing value estimation methods for DNA microarrays. Bioinformatics 17:520-525, 2001 (Pubitemid 32600498)
9. Cheson BD, Greenberg PL, Bennett JM, et al: Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood 108:419-425, 2006 (Pubitemid 44061337)
10. Cheson BD, Bennett JM, Kopecky KJ, et al: Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol 21:4642-4649, 2003 (Pubitemid 46594039)
11. Greenberg P, Cox C, LeBeau MM, et al: International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 89:2079-2088, 1997 (Pubitemid 27132124)
12. Soriano AO, Yang H, Faderl S, et al: Safety and clinical activity of the combination of 5-azacytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome. Blood 110:2302-2308, 2007 (Pubitemid 47523148)
13. Silverman LR, Fenaux P, Mufti GJ, et al: Continued azacitidine therapy beyond time of first response improves quality of response in patients with higher-risk myelodysplastic syndromes. Cancer [Epub ahead of print on January 10, 2011]
14. Lyons RM, Cosgriff TM, Modi SS, et al: Hematologic response to three alternative dosing schedules of azacitidine in patients with myelodysplastic syndromes. J Clin Oncol 27:1850-1856, 2009